Wolf‐dieter Ludwig

Wolf‐dieter Ludwig's AcademicInfluence.com Rankings

Wolf‐dieter Ludwig

Biology

#11323

World Rank

#14711

Historical Rank

Immunology

#727

World Rank

#749

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Wolf‐dieter Ludwig Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wolf‐dieter Ludwig's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). (1995) (1451)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (2006) (833)
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. (2010) (697)
Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. (2000) (681)
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. (1994) (660)
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood (1998) (617)
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. (2007) (536)
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 (2000) (524)
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 (2010) (447)
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. (2009) (439)
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. (1999) (398)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. (2012) (388)
Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. (1985) (363)
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. (1985) (358)
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. (1999) (346)
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. (1999) (345)
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. (2000) (337)
The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. (2004) (330)
Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials (1997) (308)
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. (1995) (301)
Improved outcome in adult B-cell acute lymphoblastic leukemia. (1996) (293)
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. (2005) (287)
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. (2006) (273)
TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). (1991) (269)
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. (2005) (267)
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. (2011) (261)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group (2017) (243)
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. (2007) (222)
Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). (2000) (213)
Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation. (1993) (192)
Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group (1984) (192)
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. (1993) (191)
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis (1989) (190)
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. (2006) (190)
Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. (1995) (189)
High Expression Levels of X-Linked Inhibitor of Apoptosis Protein and Survivin Correlate with Poor Overall Survival in Childhood de Novo Acute Myeloid Leukemia (2004) (185)
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. (2003) (183)
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. (1992) (182)
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. (1998) (178)
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. (2011) (173)
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia (2000) (172)
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. (2000) (171)
Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo (2000) (170)
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. (1996) (170)
Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. (1995) (169)
Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. (1999) (168)
The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). (1998) (162)
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. (1991) (155)
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. (2000) (153)
Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. (1991) (153)
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) (2009) (151)
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol (2010) (144)
Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible (2008) (143)
Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes (1993) (142)
Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. (1992) (141)
Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. (2006) (136)
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. (2006) (134)
MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. (1998) (131)
CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. (1998) (127)
Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. (1989) (126)
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function (2010) (126)
Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. (2006) (120)
Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. (1993) (120)
Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL (2005) (119)
IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. (2018) (117)
Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. (2005) (115)
Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). (1994) (113)
High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. (2009) (110)
Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia. (1989) (108)
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. (2004) (107)
Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations (2010) (103)
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG (2009) (99)
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia (2012) (98)
Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (1996) (96)
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. (2010) (95)
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients (2000) (94)
Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. (2000) (94)
Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. (1997) (93)
CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease (2004) (93)
Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. (1989) (93)
High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. (2007) (91)
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity (2001) (90)
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. (2007) (88)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. (2003) (86)
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype (2004) (86)
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics (1999) (86)
High-Level Secretion of Tumor Necrosis Factor-alpha Contributes to Hematopoietic Failure in Hairy Cell Leukemia (1989) (86)
AIEOP‐BFM Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia (2018) (86)
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. (1997) (84)
Blood dyscrasias induced by psychotropic drugs. (2004) (84)
The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia (2001) (83)
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray (2008) (80)
Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012 (2015) (77)
Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients (2001) (76)
Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases (2002) (75)
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. (2010) (74)
Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. (1997) (74)
Impact of immunophenotyping on management of acute leukemias. (1999) (73)
Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. (1994) (72)
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 (2000) (71)
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review (2004) (70)
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia (2013) (69)
Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. (2000) (68)
In vivo expression of survivin and its splice variant survivin‐2B: Impact on clinical outcome in acute myeloid leukemia (2006) (67)
Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. (1999) (67)
Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species. (2005) (66)
Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia (1998) (66)
Correlation of protein expression and gene expression in acute leukemia (2003) (66)
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. (2001) (65)
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. (2009) (65)
Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction (2009) (65)
Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12 (1998) (64)
Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. (1992) (63)
Expression and prognostic significance of different mRNA 5′‐end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration (2008) (61)
Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection—case report and review of the literature (2004) (61)
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia (2015) (59)
Loss of heterozygosity on chromosome 6q14–q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma (2006) (58)
2 Immunophenotypic classification of acute lymphoblastic leukaemia (1994) (58)
Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation (2001) (57)
Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact (2008) (57)
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). (2017) (57)
The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. (1995) (53)
Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans’ cell sarcoma: evidence for hematopoietic plasticity (2010) (53)
Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. (1997) (53)
Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. (1996) (53)
Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia (2006) (53)
Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group. (1993) (52)
The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group. (1992) (52)
dic(9; 20): A new recurrent chromosome abnormality in adult acute lymphoblastic leukemia (1995) (51)
tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. (1993) (51)
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. (1987) (51)
Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells (1997) (51)
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. (1992) (51)
The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event (1995) (51)
Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia. (1993) (51)
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. (1991) (50)
Constitutive expression levels of CD95 and Bcl‐2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia (2000) (49)
Immunophenotypic and immunogenotypic characteristics of TCRγδ+ T cell acute lymphoblastic leukemia (1999) (48)
Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2 (2001) (47)
High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia (1986) (47)
Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL. (1994) (47)
Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells. (1996) (46)
Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia (2007) (46)
Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000 (2013) (46)
In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. (2002) (46)
Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses. (1993) (45)
Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11). (1994) (45)
NONSEGMENTAL VITILIGO: DECREASE OF THE CD45RA+ T‐CELL SUBSET AND EVIDENCE EOR PERIPHERAL T‐CELL ACTIVATION (1992) (45)
Transforming growth factor-beta 1 interferes with the proliferation-inducing activity of stem cell factor in myelogenous leukemia blasts through functional down-regulation of the c-kit proto-oncogene product. (1993) (43)
Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. (1993) (43)
Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients (1995) (42)
Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. (1998) (41)
Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis (2002) (41)
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment (2005) (41)
Immunophenotypic and Genotypic Features , Clinical Characteristics , and Treatment Outcome of Adult ProB Acute Lymphoblastic Leukemia : Results of the German Multicenter Trials (1998) (41)
Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). (2006) (40)
Acute Myeloid Leukemia with Translocation (8;21). Cytomorphology, Dysplasia and Prognostic Factors in 41 Cases (1996) (40)
Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) (2005) (39)
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. (1996) (39)
The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias (1998) (39)
Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies (1996) (39)
High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia (1998) (37)
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies (2012) (37)
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. (1989) (36)
Acute myeloid leukemia: treatment over 60. (2002) (35)
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. (2012) (35)
Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH) (1998) (35)
Mutation analysis of CD95 (APO‐1/Fas) in childhood B‐lineage acute lymphoblastic leukaemia (1998) (34)
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. (1993) (34)
Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. (1996) (34)
The prognostic significance of antigen expression in leukaemia. (2003) (34)
The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia (2004) (33)
Expression of intercellular adhesion molecule 1 (ICAM‐1) in childhood acute lymphoblastic leukaemia: correlation with clinical features and outcome (1997) (33)
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. (1996) (32)
Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis (2005) (32)
Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias (2006) (32)
Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003. (2007) (31)
Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies. (1993) (31)
G protein subunit G alpha 16 expression is restricted to progenitor B cells during human B-cell differentiation. (1995) (31)
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol (2014) (31)
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia (2004) (30)
Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping (2007) (29)
Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. (2006) (29)
Functional expression of c-kit by acute myelogenous leukemia blasts is enhanced by tumor necrosis factor-alpha through posttranscriptional mRNA stabilization by a labile protein. (1992) (29)
CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12 (2012) (28)
New insights into the biology of Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia using a combination of May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques at the single cell level (1997) (28)
Morphological and cytochemical findings in 150 cases of T‐lineage acute lymphoblastic leukaemia in adults (1997) (27)
Immunophenotypic classification of acute lymphoblastic leukaemia. (1994) (27)
[Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. (1994) (27)
Suggestions for improving the design of clinical trials in multiple sclerosis—results of a systematic analysis of completed phase III trials (2019) (26)
Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukemia. Case report and review of the literature. (1986) (26)
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis (2019) (26)
Immunophenotypic and clinical features of T‐cell receptor γδ+ T‐lineage acute lymphoblastic leukaemia (1998) (25)
Peripheral blood sCD3− CD4+ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma (2014) (25)
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. (2017) (25)
Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease (2008) (25)
Clinical characteristics and treatment outcome of infants with non‐Hodgkin lymphoma (2007) (25)
Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). (2004) (25)
Chromosomal abnormalities in adult acute lymphoblastic leukemia: results of the German ALL/AUL Study Group. (1993) (24)
Near-tetraploid acute myeloid leukemias: an EGIL retrospective study of 25 cases (2006) (24)
Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group. (1992) (24)
Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome (2012) (24)
Does the pharmaceutical industry influence guidelines?: two examples from Germany. (2013) (23)
Lineage Classification of Childhood Acute Lymphoblastic Leukemia according to the EGIL Recommendations: Results of the ALL-BFM 2000 Trial (2013) (23)
Immunosuppressive effects of recombinant interferon‐α during long‐term treatment of cancer patients (1989) (23)
Rearrangements of T-cell receptor delta, gamma and beta genes in acute myeloid leukemia coexpressing T-lymphoid features. (1992) (23)
Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. (1992) (23)
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. (2002) (23)
Acute myeloid and T‐cell acute lymphoblastic leukaemia with aberrant antigen expression exhibit similar TCRδ gene rearrangements (1996) (22)
Molecular characterization of illegitimate TCRδ gene rearrangements in acute myeloid leukaemia (1994) (22)
Calla-positive acute leukaemia with t(5q;14q) translocation and hypereosinophilia--a unique entity? (1989) (22)
A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. (2009) (22)
Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells (1998) (21)
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy (2001) (21)
Characterization of the monocyte-specific esterase (MSE) gene. (1994) (21)
PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. A PROSPECTIVE STUDY OF THE INTERNATIONL BFM STUDY GROUP. (1998) (21)
Human Lyb‐2 homolog CD72 is a marker for progenitor B‐cell leukemias (1992) (20)
Characterisation of insulin-like growth factor I receptors of human acute lymphoblastic leukaemia (ALL) cell lines and primary ALL cells. (1992) (20)
Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group. (1990) (20)
Anemia and survival in childhood acute lymphoblastic leukemia (2008) (19)
CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. (2010) (19)
Ph1 positive blast crisis of chronic myeloid leukaemia exhibiting features characteristic of early T blasts. (2009) (19)
Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia. (1993) (19)
Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas. (1998) (19)
A comparison of membrane marker phenotypes in hairy-cell leukemia and phorbol-ester induced B-cll cells using monoclonal antibodies. (1985) (19)
[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 1: Classification and allocation to strategic therapy groups. BIF study group]. (1994) (19)
Acute leukemia with chromosome translocation (4; 11): 7 new patients and analysis of 71 cases (1987) (18)
Synergy of interleukin 3 and tumor necrosis factor alpha in stimulating clonal growth of acute myelogenous leukemia blasts is the result of induction of secondary hematopoietic cytokines by tumor necrosis factor alpha. (1992) (18)
Differences in the expression pattern of apoptosis-related molecules between childhood and adult de novo acute myeloid leukemia. (2004) (17)
Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM / AF 10-positive leukemia (17)
Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. (1999) (16)
Staging and monitoring of malignant lymphoma of the bone: comparison of 67Ga scintigraphy and MRI. (1999) (16)
BLAST CRISIS IN CML SHOWING EARLY T‐LYMPHOBLASTIC TRANSFORMATION (1984) (16)
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. (2006) (16)
Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. (2008) (16)
CD 95 ( APO-1 / Fas ) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia (1998) (15)
Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples. (1992) (15)
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study (2018) (15)
Expression of cell–cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia (2010) (15)
Childhood near‐tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases (2010) (15)
Overexpression of the Raf-1 proto-oncogene in human myeloid leukemia. (1994) (15)
New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD). (2009) (15)
Recent Advances in Cell Biology of Acute Leukemia (1993) (15)
The role of GM-CSF in the treatment of acute myeloid leukemia. (1993) (15)
Incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. (1993) (15)
Expanded T gamma cell populations with the morphology of large granular lymphocytes -- I. Immunological, clinical and morphological characterization. (1983) (15)
Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients. (1992) (15)
Cytogenetic and molecular characterization of a patient with simultaneous B‐cell chronic lymphocytic leukemia and peripheral T‐cell lymphoma (2001) (14)
Recombinant human GM-CSF following chemotherapy in high-risk AML. (1990) (14)
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML. (1992) (14)
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary? (2000) (14)
Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia. (1988) (14)
Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemias (2008) (14)
Genome wide molecular analysis of minimally differentiated acute myeloid leukemia (2009) (14)
Immunophenotype of acute myeloid leukemia: correlation with morphological characteristics and therapy response. (1993) (13)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow (2003) (13)
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. (1991) (12)
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. (2021) (12)
Expression of CD56 defines a distinct subgroup in childhood T‐ALL with inferior outcome. Results of the ALL‐BFM 2000 trial (2018) (12)
Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics. (2010) (12)
Chronic Lymphocytic Leukemia (B-CLL) and Immunocytoma (LP-IC): Clinical and Prognostic Relevance of this Distinction. (1991) (12)
Translocation t(1;22) mimicking t(1;19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting. (1993) (12)
Sequential Analysis of P-Glycoprotein Expression in Childhood Acute Lymphoblastic Leukemia (1992) (11)
[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases]. (1998) (11)
Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells. (1993) (11)
t(5;14)(q33-34;q11), a new recurring cytogenetic abnormality in childhood acute leukemia. (1994) (11)
MITOZANTRONE AND HIGH-DOSE CYTARABINE IN REFRACTORY ADULT ACUTE MYELOID LEUKAEMIA (1985) (11)
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo (1993) (11)
[Acute lymphatic leukemia of the adult. Diagnosis, risk groups and therapy]. (1996) (11)
Subgroup specific therapy effects in AML: AMLCG data. (2004) (10)
Acute Leukemias Impact of CD 133 ( AC 133 ) and CD 90 expression analysis for acute leukemia immunophenotyping (2001) (10)
High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008) (2013) (10)
Classification of Acute Leukemias (2003) (9)
Intracellular expression of CD61 precedes surface expression (1999) (9)
Clinical Features and Outcome of Children With First Marrow Relapse of Acute Lymphoblastic Leukemia Expressing BCR-ABL Fusion Transcripts (2002) (9)
DNA aneuploidy in childhood acute lymphoblastic leukemia: relation to clinical determinants and prognosis within four consecutive BFM trials. (1993) (9)
Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). (2005) (9)
Clinical importance of T-ALL subclassification according to thymic or prethymic maturation stage. (1990) (9)
Remission induction therapy: the more intensive the better? (2001) (9)
Chemotherapy Intensity and Long-Term Outcome in AML (1994) (9)
[The relation between publication bias and clinical trials funding]. (2010) (9)
Drug information by public health and regulatory institutions: Results of an 8-country survey in Europe. (2017) (9)
Alveolar rhabdomyosarcoma with bone marrow infiltration mimicking haematological neoplasia (2002) (8)
Emergence of translocation t(9;11)‐positive leukemia during treatment of childhood acute lymphoblastic leukemia (2004) (8)
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. (1993) (8)
Risk Adapted Treatment in Childhood Acute Lymphoblastic Leukemia: Data from the Berlin-Frankfurt-Münster Group (1997) (8)
Incidence, Biologic Features and Treatment Outcome of Myeloid-Antigen-Positive Acute Lymphoblastic Leukemia (My + ALL) (1994) (8)
Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia. (1998) (8)
Molecular characterization and clinical course of MLL-ACTN4 rearrangement in therapy-related hematologic malignancies (2014) (8)
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results. (1989) (7)
[Acute myeloid leukemia in children with Down syndrome]. (1995) (7)
Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial. (1987) (7)
Cytogenetics of childhood acute lymphoblastic leukemia in multicenter trials. (1990) (7)
Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial. (2009) (7)
[Therapy of Zenker's diverticulum]. (2002) (7)
[Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession]. (2012) (7)
Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia. (1995) (7)
GM-CSF Multiple Course Priming and Long-Term Administration in Newly Diagnosed Acute Myeloid Leukemia: Comparison of Three Different GM-CSF Routes and Schedules with No GM-CSF (1994) (7)
Molecular characterization of illegitimate TCR delta gene rearrangements in acute myeloid leukaemia. (1994) (7)
Ras point mutations occur in acute myeloid leukemia with illegitimate T-cell receptor delta gene rearrangement. (1994) (7)
Activating NOTCH1 Mutations Predict Favorable Early Treatment Response and Long Term Outcome in Child- hood Precursor T-Cell Lymphoblastic Leukemia Short Title: NOTCH1mutations predict outcome in pediatric T-ALL (2006) (6)
Experiencing the risk of overutilising opioids among patients with chronic non-cancer pain in ambulatory care (ERONA): the protocol of an exploratory, randomised controlled trial (2020) (6)
T-cell acute childhood lymphoblastic leukemia with chromosome 14q11 anomaly: a morphologic, immunologic, and cytogenetic analysis of 10 patients (1988) (6)
Routine immunophenotyping of acute leukemias (2005) (6)
CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12 (2012) (6)
High-dose cytosine-arabinoside and mitoxantrone in refractory acute myeloid leukemia: a clinical phase I/II-study. (1986) (6)
[Classification of AML by morphologic, immunologic and cytogenetic criteria. Review with reference to subtypes in the AML-BFM-87 study]. (1993) (6)
The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG) (2014) (6)
Atypical presentation of Hodgkin's disease in a patient at risk for the acquired immunodeficiency syndrome. (1988) (6)
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse. (1990) (6)
The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment (2014) (6)
Salvage Therapy for Relapsed Mediastinal B-Cell Lymphoma with Allogeneic HLA-Identical Related Donor Bone Marrow Transplantation, Donor Lymphocyte Infusion and IDEC-C2B8 (2000) (6)
GM-CSF in Chemotherapy for Newly Diagnosed AML: Multiple Course Priming and Longterm Administration Compared to Chemotherapy Alone (1994) (6)
MONOCLONAL ANTIBODY WGM1 DIRECTED AGAINST PROTEINASE 3: AN IMMUNOHISTOCHEMICAL MARKER FOR NAPHTHOL ASD CHLOROACETATE (1996) (6)
First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany (1999) (5)
CD 11 b is a therapy resistance – and minimal residual disease – specific marker in precursor B-cell acute lymphoblastic leukemia (2010) (5)
Treatment of Ph+ and t(4;11)+ Acute Lymphoblastic Leukemia in Adults (1998) (5)
p69,71 antigen complex detected by monoclonal antibody Leu 1 in the identification of particular stages of malignant B-cell differentiation. (2009) (5)
Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013. (2015) (5)
The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study. (2007) (5)
[New drugs in oncology--features of clinical trials for market authorisation and arguments for the rapid implementation of independent clinical trials following approval]. (2013) (5)
Flow cytometric immunophenotyping of acute lymphoblastic leukemia: is the time ready for consensus the guidelines? (2002) (5)
Acquired deficiency of coagulation factor XIII—possible evidence for a new link between coagulation and infection from a case (2013) (5)
Does the Pharmaceutical Industry Influence Guidelines (2013) (5)
GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. (1992) (5)
[Clinical trials in oncology: deficits and proposals for solution]. (2011) (4)
A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy (2017) (4)
Older Age Is An Independent Risk Factor in AML (2008) (4)
[Diagnosis of acute leukemia with morphologic, immunologic and cytogenetic procedures]. (1993) (4)
Submicroscopic genomic rearrangements change gene expression in T‐cell large granular lymphocyte leukemia (2014) (4)
Chronic lymphocytic leukemia B-lymphocytes forming SRBC-rosettes not due to an anti-SRBC activity of monoclonal surface immunoglobulin. (1985) (4)
NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia (2017) (4)
In vitro effects of G-CSF, GM-CSF, and IL-3 on leukemic cells of children with acute nonlymphoblastic leukemia. (1990) (4)
Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group (2008) (4)
Arbobacteria - Pathogens Transmittable by Arthropods. (2008) (4)
Use of monoclonal antibodies as a diagnostic tool in human leukemia (1983) (4)
[Conflicts of interest and clinical drug trials -- impact of the pharmaceutical industry and the impingement on the integrity of medical science]. (2009) (4)
Heterogeneity of HRX-FEL Fusion Transcripts in Adult and Pediatric t(4;11) ALL (1996) (4)
Immunological Classification of “Unclassifiable” Acute Leukemia (1986) (4)
Mitogenic Effect of Human Stem Cell Factor Alone or in Combination with G-CSF, GM-CSF, and IL-3 on Fresh Leukemic Blasts from Patients with Stem Cell Factor Receptor-Positive Acute Myeloid Leukemia (1992) (4)
Transcript Synthesis and Surface Expression of the Interleukin-2 Receptor ( a-, p-, and ?-Chain ) by Normal and Malignant Myeloid Cells (2002) (4)
Treatment of AML in biological subgroups (2005) (3)
[Scientists call for a reevaluation of HPV vaccination and an end to the misleading information]. (2009) (3)
Apheresis‐related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation (2012) (3)
The Favorable Effect of Activating NOTCH1 Receptor Mutations On Long Term Outcome in T-ALL Is Treatment Related and Can Be Separated From NOTCH Pathway Activation by FBXW7 Loss of Function. (2009) (3)
[Expression and significance of apoptosis protein inhibitor survivin and XIAP, in patients with myelodysplastic syndromes and in the cell line MUTZ-1]. (2004) (3)
OF THE STEM CELL FACTOR RECEPTOR C-KIT ( CD 117 ) IN ACUTE LEUKEMIAS (2005) (3)
Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia. (2007) (3)
Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia. (1987) (3)
The Role of Maintenance Chemotherapy, Immunotherapy, Induction Dose Reduction in Elderly Patients and Double Induction in the Treatment of Adult Acute Myeloid Leukemia. Four Randomized Studies of the AML Cooperative Group1 (1989) (3)
Acute Megakaryoblastic Leukemia in Children without Down’s Syndrome. (2004) (3)
Heterogeneity of V delta 2 TCR delta gene rearrangements in acute myeloid leukemia. (1994) (3)
A direct and effective immunomagnetic method for bone marrow purging in non-T ALL malignancies. The use of an anti-HLA-DR antibody gives sustained engraftment. (1994) (3)
Surface marker analysis by monoclonal antibodies: a valuable technique in childhood acute myeloid leukemia. (1987) (3)
[Involvement of mitochondrial membrane potential in the homoharringtonine induced apoptosis of leukemic T-cells]. (2001) (3)
Hematologic and Therapeutic Effects of High-Dose AraC/Mitoxantrone (HAM) in the Induction Treatment of Patients with Newly Diagnosed AML. A Trial by AML Cooperative Group (1996) (3)
Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000. (2007) (3)
[Diagnosis of tumors of the small intestine with the aid of CT contrast enema. Sellink CT technique evaluated in 63 patients]. (2002) (3)
High Interleukin 15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia with Involvement of the Central Nervous System. (2006) (2)
Preclinical studies of T-cell-mediated immune responses against autologous tumor cells in patients with acute leukemia. (1993) (2)
CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient’s Outcome Differ According to the Subtype. (2005) (2)
Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo. (1991) (2)
Flow-Cytometric Immunophenotyping of Acute Leukemias (2009) (2)
[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. (2012) (2)
Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95. (2004) (2)
[Differential diagnosis of intra- and perilienal tumors by use of a RES-specific MRI contrast agent]. (2004) (2)
[Use of Ga-67 SPECT in patients with malignant lymphoma after primary chemotherapy for further treatment planning: comparison with spiral CT]. (1997) (2)
Cytomorphological results and dysplastic features as prognostic factors in 41 cases with acute myeloid leukemia (AML) and translocation (1994) (2)
The CALM/AF10 Fusion: Molecular Analysis of the Fusion Transcripts in 13 Cases of AML and ALL; Gene Expression Profiling Reveals HOX Gene Deregulation. (2004) (2)
Clinical Relevance of Chromosomal Aberrations in Childhood ALL: Cytogenetic Data of the German Therapy Studies (1994) (2)
Flow-Cytometry Methods for the Detection of Residual Leukemia (2003) (2)
T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial (2016) (2)
[Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy]. (2002) (2)
CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG ). (2004) (2)
Cytogenetics and Clonal Evolution in Childhood Acute Lymphoblastic Leukemia (ALL) (1996) (2)
Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life (2000) (2)
Molecular Characterization of the Translocation (10;11)(p13;q14): MLLandCALMare Fused toAF10in Morphologically Different Subsets of Acute Leukemia (2001) (1)
[Immunophenotyping of acute lymphatic leukemia: diagnostic aspects and clinical relevance]. (1994) (1)
[Hematopoietic growth factors. Possibilities and limitations]. (2010) (1)
High-Dose Cytosine Arabinoside and Mitoxantrone (HAM) in the Treatment of Acute Leukemias: Results of Salvage and First Line Treatment (1992) (1)
Growth Factors in AML: Updates (1997) (1)
XVIIth International Symposium on Technological Innovations in Laboratory Hematology (2004) (1)
Biological Entities in Acute Myelogenous Leukemia According to Morphological, Cytogenetic and Immunological Criteria: Data of Study AML-BFM-87 (1996) (1)
Group report event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Intensive ALL-type therapy without local radiotherapy provides a 90% (2013) (1)
[Biosimilars in oncology: a therapeutic alternative to the reference products?] (2016) (1)
Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo. (1993) (1)
Frequent Loss of the SLP-65 Adapter Protein in Childhood Acute B-Precursor Lymphoblastic Leukemia (ALL) with TEL/AML1 Rearrangement. (2005) (1)
Molecular Targets of Glucocorticoids in Context of Apoptosis Induction in Childhood Precursor T-Cell ALL (T-ALL). (2004) (1)
B-cell function in AIDS (1985) (1)
[Improving drug safety in Germany: an alliance between the government and the medical profession]. (2008) (1)
Cytochrome C Related Caspase Activation Determines Treatment Response in Childhood B- Precursor ALL. (2004) (1)
Minimal residual disease detection by flow cytometry. (2004) (1)
NOTCH1 Activation Neutralizes the Unfavorable Prognostic Effect of PTEN Mutations in BFM-Treated Children with T-ALL (2011) (1)
Lymphokine-activated killer (LAK) cells against human leukemia: augmentation of LAK-cell cytotoxicity by combinations of lymphokines or cytokines. (1990) (1)
Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG (2001) (1)
Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia (2001) (1)
Acute Myeloid Leukemia (AML): The Role of Maintenance Chemo- therapy (2004) (1)
Treatment of refractory acute myeloid leukemia with high-dose cytosine arabinoside and mitoxantrone in combination (1986) (1)
13 How Can Better Evidence Be Delivered ? (2011) (1)
Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). (2005) (1)
Classification of acute leukemias: reply from EGIL to Dr van Dongen. (1996) (1)
Induction of lymphokine-activated killer cells against human leukemia cells in vitro (1989) (1)
Myeloperoxidase: Gene Demethylation and Expression in Acute Myeloid Leukemias (1992) (1)
Direct-to-Consumer Advertising (2011) (1)
Intensified Therapy for AML:The Role of the HAM Combination (1998) (1)
Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Following Chemotherapy in Patients with High-Risk AML (1992) (1)
[BALTOMA--long-term follow-up]. (2002) (1)
Hematopoietic Recovery and Priming — Therapeutic Effects of GM-CSF in the Treatment of AML (1996) (1)
Age Predilection of Distinct Phenotypically Defined Subgroups of Non-T Cell ALL: Studies Using B Cell-Restricted or -Associated Monoclonal Antibodies in 359 Patients (1986) (1)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prednisone Response Is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia (2016) (0)
[Open questions in the drug therapy of tumors with new active substances]. (2010) (0)
leukemia and long term outcome in child-hood precursor T-cell lymphoblastic Activating NOTCH1 mutations predict favorable early treatment response (2013) (0)
Coincident change of cellular function and phenotype in the course of a suppressor T cell acute lymphocytic leukaemia. (1985) (0)
The Susceptibility of Human Leukemia Cells to Allogeneic and Autologous Lymphokine-Activated Killer Cells and Augmentation of the Susceptibility by Exposure of Target Cells to Cytotoxic Drugs In Vitro and In Vivo (1992) (0)
In reply. (2014) (0)
[Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies]. (2011) (0)
Current Approaches in the Prevention of Invasive Aspergillosis (1997) (0)
FS-HAI for Relapsed AML (2003) (0)
Human Cytomegalovirus: Degranulation Is a Prominent Feature of Functionally Impaired pp65- and IE-1-Specific T-Cells in Patients after Allogeneic Stem Cell Transplantation (2008) (0)
Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL) (2008) (0)
Mobilization of Peripheral Blood Stem Cells after Intensive Induction and Consolidation Therapy in Adult Patients with De Novo AML (2000) (0)
Alteration of blast phenotype after low-dose cytarabine in children with acute myeloid leukemia. (1987) (0)
[Malignant lymphoma: magnetic resonance tomography findings in residual supradiaphragmatic space-occupying lesions]. (1999) (0)
Differential Gene Expression in Leukemic Cells from Bone Marrow (BM) and Peripheral Blood (PB) of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL). (2004) (0)
TREATMENT OF CHILDHOOD ALL 3123 an increased leukemic cell (2002) (0)
Gene Expression in Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL Displays a Common Shift towards Terminally Differentiated B Cells and a Cytoreduction-Associated Impairment of the Translational Machinery. (2005) (0)
[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges]. (2019) (0)
Molecular Biological Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia (1997) (0)
[Overtreatment at the End of Life in Oncology]. (2022) (0)
Activating NOTCH1 Mutations Are Associated with Good Treatment Response in Childhood T-Cell Acute Lymphoblastic Leukemia. (2005) (0)
Changes in development and evaluation of new cancer drugs: what is needed to guide practice? (2012) (0)
An effective, direct immunomagnetic procedure for purging acute lymphoblastic leukemia cells from human bone marrow (1995) (0)
Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets. (2006) (0)
Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group. (2009) (0)
Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse (2011) (0)
Frequency and prognostic value of dysmyelopoiesis in 114 patients with de novo acute myeloid leukemia (AML) in an ongoing study (1994) (0)
High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients (2011) (0)
Chemotherapy for Adult Acute Myeloid Leukemia: Study Results from the Acute Myeloid Leukemia Cooperative Group and Overview (1993) (0)
Prognostic Analysis of Pre-Transplant CD26-Positive Lymphocytes and CD26bright/CD45RO-Positive Memory T-Cell Levels in Patients Receiving an Autologous Hematopoietic Progenitor-Cell Transplant. (2007) (0)
[Characterization of the leukemic cell population in a patient with T-ALL at disease beginning and in recurrence: parallel changes in phenotypic and functional behavior]. (1985) (0)
[Patient education responsibility, specialty and administration information from the internal medicine viewpoint]. (1997) (0)
Assessment of Response to Therapy in Primary Myeloid Sarcoma Using Positron Emission Tomography/Computer Tomography Imaging: A Case Report (2008) (0)
Case Report: A Patient with Haemorrhagic Bleeding, an Acquired Factor VIII Inhibitor and Massive Pulmonary Embolism. (2007) (0)
[Interview -- drug legislation -- reporting unexpected adverse drug reactions]. (2009) (0)
[Flow-cytometric immunophenotyping in clinical diagnostics]. (2016) (0)
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM). (1990) (0)
Monitoring of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia — Preliminary Data from a Prospective Study (1998) (0)
[Editorial comment on Krege S. et al: off-label use: an unsolved problem]. (2007) (0)
outcome in childhood AML Intact apoptosis signalling in myeloid leukaemia cells determines treatment (2013) (0)
Interrelationship of Hairy Cell Leukemia and Phorbol Ester Induced B-Cell “Lymphocytes” as Demonstrated by Monoclonal Antibodies (1985) (0)
Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML). (2006) (0)
Aldehyde Dehydrogenase-Positive Hematopoetic Progenitor Cells in Peripheral Blood and Progenitor Cell Apheresis Products: Characterization and Correlation with Kinetics of Engraftment. (2005) (0)
[Definition of malignant histiocytosis and large cell anaplastic (Ki-1) lymphoma in children]. (1989) (0)
Feasibility of Multicentric Assessment of MRD in All by Flow-Cytometry: Standardization and Experience of the I-BFM-ALL FCM-MRD Study Group. (2004) (0)
Significance of Copy Number Alterations for Molecular Treatment Response in Childhood Acute Lymphoblastic Leukemia. (2007) (0)
CD11b Is a Therapy-Induced Marker for Monitoring Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. (2007) (0)
A prospective, randomised study on the use of well-ﬁtting masks for prevention of invasive aspergillosis in high-risk patients (2009) (0)
leukemia : results in 3184 patients of the AIEOP-BFM ALL 2000 study children and adolescents with B-cell precursor acute lymphoblastic Molecular response to treatment redefines all prognostic factors in (2010) (0)
Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia (1998) (0)
Karyotypic Abnormalities in Secondary Leukemia of Children (1997) (0)
Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG) (2011) (0)
treatment outcome in childhood AML Intact apoptosis signaling in myeloid leukemia cells determines (2010) (0)
Glucocorticoid Therapy Targets Proliferation, Differentiation and Bcl-2 Dependent Survival Signaling in ALL Blasts. (2006) (0)
PCR as a Diagnostic Tool in ALL: A Comparison Between Cytogenetic and Polymerase Chain Reaction Analysis in Pediatric Patients with Acute Lymphoblastic Leukemia (1994) (0)
Hematopoietic Growth Factors: Supportive and Priming Effects in AML (1998) (0)
[Therapy of malignant lymphoma]. (1990) (0)
The Receptor Tyrosine Kinase ~ 1 8 5 ~ ~ ~ ~ Is Expressed on a Subset of B-Lymphoid Blasts Prom Patients With Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia (2002) (0)
Monitoring of PML-RAR alpha in Patients with Acute Promyelocytic Leukemia (APL) by RT-PCR (1998) (0)
Network German Low Grade Lymphoma Study Group ( GLSG ) and the European Mantle Cell Lymphoma (2007) (0)
Abnormal marker expression in acute leukemia (AL) characterized by monoclonal antibodies and flow cytometry. (1987) (0)
Interleukin-2-Induced Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia: Improvement of Cytotoxicity by Combinations of Lymphokines or Cytokines (1990) (0)
Prospective Multicenter Study for Patients with Therapy - Related Acute Myeloid Leukemia (AML) Using Intensive Induction and Postremission Therapy. (2006) (0)
Mitochondrial genome variants in non‐remitting ALL of childhood (2011) (0)
The Expression of the Adaptor Protein SLP-65 Is Freqently Lost in Childhood B-Lineage Acute Lymphoblastic Leukemia (ALL). (2004) (0)
GM-CSF in the treatment of acute myeloid leukemia. (1992) (0)
The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile. (2007) (0)
cell lymphoma A new prognostic index (MIPI) for patients with advanced-stage mantle (2008) (0)
High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG. (2007) (0)
Characterization of the t(7;12) chromosomal translocation in infant AMLs: coexpression of T-cell markers, distinct expression of homeobox genes and inhibition of the non-canonical Nf-kappaB pathway (2009) (0)
Biologic Determinants for AML Therapy (1998) (0)
Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG. (2006) (0)
Regulation of protooncogenes and cytokine genes in acute lymphoblastic leukemia. (1993) (0)
Salvage Therapy of Adult ALL (1996) (0)
Therapeutic and Prognostic Factors in the Management of Acute Myeloid Leukemia (1997) (0)
[Treatment of adult acute lymphoblastic leukemia]. (1999) (0)
Trial NHL-BFM 90 Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored (2013) (0)
Altered Expression and Signalling of Bone Morphogenetic Protein Receptor 1A (BMPR-1A) and Enhanced Hematopoietic Progenitor Cell Growth in Long-Term Stromal Culture Assays from Two Patients with a Myeloproliferative Syndrome and Pulmonary Hypertension. (2006) (0)
Gene Expression Analysis of Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL. (2004) (0)
Effect of Chemotherapy Followed by GM-CSF for Acute Leukemias at Higher Age or After Relapse (1990) (0)
BALTOMe - ein Langzeitverlauf [BALTOMA - long-term follow-up] (2002) (0)
High Expression Levels of Iaps Predict Poor Overall Survival in Childhood De Novo Acute Myeloid Leukemia. (2004) (0)
lymphoblastic leukemia interleukin 7, and early cytoreduction in vivo in childhood T-cell acute apoptotic cell death in context of maturation stage, responsiveness to In vitro susceptibility to dexamethasone- and doxorubicin-induced (2013) (0)
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial (2011) (0)
Site-specific Deletions Involving the ta/-1 and s/l Genes Are Restricted to Cells of the T Cell Receptor cd~ Lineage: T Cell Receptor ~ Gene Deletion Mechanism Affects Multiple Genes By Timo M. Breit,* Ellen J. Mol,* Ingrid L. M. Wolvers-Tettero,* (1993) (0)
HOX-Gene Expression and Inhibition of the Non-Canonical NF-KappaB Pathway in t(7;12) Leukemias (2008) (0)
In Vitro Sensitivity to Chemotherapy-Induced Apoptosis in CD2+ve and CD2-ve Childhood T-All (2003) (0)
Prognostic Value of Dysmyelopoiesis in 128 Patients with De Novo Acute Myeloid Leukemia (1997) (0)
Biosimilars in Germany: guidance of the Drug Commission of the German Medical Association (2017) (0)
Involvement of BCL-2 and Bax in the IL-7-lnduced Inhibition of Spontaneous Apoptosis in Childhood T-ALL (2001) (0)
Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment (2011) (0)
Monoclonal antibodies recognizing T-cells (Leu 1) and transferrin receptor (OKT 9) crossreact with malignant B-cells of distinct differentiation stages. (1984) (0)
All-Trans Retinoic Acid (ATRA) Combined with Double Induction Strategy in Acute Promyelocytic Leukemia (APL). Preliminary Results (1998) (0)
Treatment of relapsed acute lymphoblastic leukemia (ALL): Improved results in GMALL studies but optimisation is an ongoing challenge (2011) (0)
[Morphological, immunological and cytogenetic diagnosis in acute leukemias]. (1996) (0)
Favourable Treatment Outcome in Childhood AML Is Determined by Intact Apoptosis Signalling in Myeloid Leukaemia Cells. (2007) (0)
MRD-Detection by Multiparametric Flow Cytometry in Childhood Precursor B-Cell All:Predictive Impact of Early Blast Reduction Kinetics in Peripheral Blood (PB) on MRD-Level in Bone Marrow (BM) at Day 33 of the All-BFM2000 Potocol. (2004) (0)
Arbobacteria – Pathogens Transmittable by Arthropods (2008) (0)
Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach (2003) (0)
[Thrombotic thrombocytopenic purpura within the scope of disseminated tumor disease]. (1987) (0)
Heterogeneity of VS2 TCR 6 Gene Rearrangements in Acute Myeloid Leukemia (1994) (0)
CD95-Mediated Apoptosis in Acute Myeloid Leukemia (AML): Dependence on Maturational Stage and Growth Characteristics in Vitro (1998) (0)
Induction of lymphokine-activated killer (LAK) cells against human leukemia cells. (1989) (0)
Cell membrane phenotypes in childhood lymphoid malignancies at relapse defined by monoclonal antibodies (MoAbs) (1986) (0)
Toxicity and Risk Factors Contributing to Delayed Methotrexate (MTX) Elimination in Adult/Elderly Patients (pts) Treated with High-Dose Methotrexate Therapy (HDMTX), a 2-Year, Single Center Survey. (2006) (0)
Cytomorphology and Clinical Outcome in 80 Patients with AML M4Eo and Inversion 16 (1997) (0)
Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study. (2004) (0)
[Legal aspects of medication prescription]. (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wolf‐dieter Ludwig?

Wolf‐dieter Ludwig is affiliated with the following schools:

Hannover Medical School

Wolf‐dieter Ludwig's Academic­Influence.com Rankings

Why Is Wolf‐dieter Ludwig Influential?

Wolf‐dieter Ludwig's Published Works

Published Works

What Schools Are Affiliated With Wolf‐dieter Ludwig?

Wolf‐dieter Ludwig's AcademicInfluence.com Rankings